Background. Large comparative trials found fidaxomicin to decrease recurrence rates relative to vancomycin for CDI. The price of fidaxomicin makes universal use cost-prohibitive. This study evaluates outcomes of patients who received fidaxomicin or vancomycin after a pathway encouraging fidaxomicin use for recurrent or serious CDI.
Methods. This was a single-center retrospective study of patients who received vancomycin or fidaxomicin for CDI during January 2012-January 2014. By protocol patients were eligible for fidaxomicin if they experienced a recurrent CDI or had 2 of 4 of: immunocompromising conditions; concomitant antibiotics; age > 65 years; lab values of WBC >15K, SCr rise 1.5x baseline, or albumin <3 gm/dL. Included patients were adults with C. difficile positive assays and acute diarrhea. All included patients were fidaxomicin-eligible per the institution protocol. Patients who failed initial therapy for the CDI episode were excluded. Baseline and clinical characteristics were collected. The primary outcome was readmissions due to recurrence of CDI within 90 days. Data were analyzed by Chi-square and t-test as appropriate and logistic regression with readmission as a binary variable was performed to determine characteristics associated with recurrence.
Results. On multivariate analysis that included treatment, severity of initial CDI, creatinine increase, and concomitant antibiotics, treatment with fidaxomicin was associated with lower risk of readmission with CDI (OR 0.33, 
